View More 2020, Scientific Sessions, Session Coverage

Investigators will review latest data from VERTIS-CV trial of SGLT2 inhibitor ertugliflozin


Estimated Read Time:

2 minutes

Christopher P. Cannon, MD
Christopher P. Cannon, MD

Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of the sodium-glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin will be presented by a panel of trial investigators during the Virtual 80th Scientific Sessions. The two-hour symposium, Results of the eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV), begins at 10:15 a.m. CT on Tuesday, June 16.

“Our primary objective in the VERTIS-CV trial was to show that ertugliflozin, a relatively new member of the SGLT2 inhibitor class of medications, did not increase risk for cardiac events compared to placebo in patients with type 2 diabetes and atherosclerotic heart disease,” said Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee.

“We will present data on cardiovascular outcomes, including heart failure, which is increasingly being recognized as a major morbidity for patients with diabetes, one associated with a much worse prognosis,” Dr. Cannon said. “The safety of this newer agent will also be presented, including effects on diabetic ketoacidosis and acute kidney injury.”

The investigators also will present an updated meta-analysis of several SGLT2 inhibitor trials, looking at overall CV endpoints, CV death, heart failure, and renal endpoints. Scientific Sessions attendees who view the virtual program will learn the latest information on this important class of drugs.

“This is the sixth large trial of SGLT2 inhibitors in patients with diabetes, and our findings will add more information to the field,” said Dr. Cannon, Education Director of Cardiovascular Innovation at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. “The recent ADA guidelines say we should add this class of drugs for patients with prior atherosclerotic heart disease, heart failure, or chronic kidney disease. This is a major change in focus for the guidelines—to choose a class of drugs for appropriate patients with diabetes that provide additional clinical benefits beyond blood sugar control. We clinicians now need to get with the guidelines.”


Already registered?
View this presentation at

Not yet registered?
Register now to access all presentations from the Virtual 80th Scientific Sessions.